{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:22:13Z","timestamp":1794007333055,"version":"4.8.0"},"reference-count":144,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.bcp.2016.11.019","type":"journal-article","created":{"date-parts":[[2016,11,21]],"date-time":"2016-11-21T15:32:10Z","timestamp":1479742330000},"page":"86-96","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":476,"special_numbering":"C","title":["Antifungals"],"prefix":"10.1016","volume":"133","author":[{"given":"Sonia","family":"Campoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 L.","family":"Adrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2016.11.019_b0005","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jof2040026","article-title":"New horizons in antifungal therapy","volume":"2","author":"Pianalto","year":"2016","journal-title":"J. Fungi"},{"key":"10.1016\/j.bcp.2016.11.019_b0010","first-page":"165rv13","article-title":"Hidden killers: human fungal infections","volume":"4","author":"Brown","year":"2012"},{"key":"10.1016\/j.bcp.2016.11.019_b0015","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.diagmicrobio.2012.02.001","article-title":"The changing epidemiology of healthcare-associated candidemia over three decades","volume":"73","author":"Diekema","year":"2012","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.bcp.2016.11.019_b0020","doi-asserted-by":"publisher","first-page":"81","DOI":"10.7326\/M13-2508","article-title":"Combination antifungal therapy for invasive aspergillosis","volume":"162","author":"Marr","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.bcp.2016.11.019_b0025","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.tim.2010.02.004","article-title":"Therapy for fungal diseases: opportunities and priorities","volume":"18","author":"Denning","year":"2010","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.bcp.2016.11.019_b0030","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1517\/13543776.2014.876993","article-title":"Novel antifungal agents: a patent review (2011-present)","volume":"24","author":"Castelli","year":"2014","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.bcp.2016.11.019_b0035","first-page":"26","article-title":"Antifungal resistance and new strategies to control fungal infections","author":"Vandeputte","year":"2012","journal-title":"Int. J. Microbiol."},{"key":"10.1016\/j.bcp.2016.11.019_b0040","doi-asserted-by":"publisher","first-page":"a019703","DOI":"10.1101\/cshperspect.a019703","article-title":"Antifungal drug development: challenges, unmet clinical needs, and new approaches","volume":"4","author":"Roemer","year":"2014","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.bcp.2016.11.019_b0045","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1126\/science.aaa6097","article-title":"How to bolster the antifungal pipeline","volume":"347","author":"Denning","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.bcp.2016.11.019_b0050","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1517\/14728214.2016.1155554","article-title":"Is there an emerging need for new antifungals?","volume":"21","author":"Perfect","year":"2016","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.bcp.2016.11.019_b0055","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1128\/CMR.12.1.40","article-title":"Current and emerging azole antifungal agents","volume":"12","author":"Sheehan","year":"1999","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.bcp.2016.11.019_b0060","first-page":"104","article-title":"Future of antimycotic therapy","volume":"3","author":"Ghannoum","year":"1997","journal-title":"Dermatol. Therapy"},{"key":"10.1016\/j.bcp.2016.11.019_b0065","first-page":"130","article-title":"Antifungal agents: mode of action in yeast cells","volume":"19","author":"Carrillo-Munoz","year":"2006","journal-title":"Rev. Esp. Quimioter."},{"key":"10.1016\/j.bcp.2016.11.019_b0070","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1021\/cr00081a015","article-title":"Cytochrome P-450 and chloroperoxidase: thiolate-ligated heme enzymes. Spectroscopic determination of their active-site structures and mechanistic implications of thiolate ligation","volume":"87","author":"Dawson","year":"1987","journal-title":"Chem. Rev."},{"key":"10.1016\/j.bcp.2016.11.019_b0075","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/0163-7258(95)00011-5","article-title":"P450 inhibitors of use in medical treatment: focus on mechanisms of action","volume":"67","author":"Bossche","year":"1995","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2016.11.019_b0080","doi-asserted-by":"publisher","DOI":"10.1007\/7355_2016_4","article-title":"Past, present and future of antifungal drug development","author":"Shukla","year":"2016","journal-title":"Top. Med. Chem."},{"key":"10.1016\/j.bcp.2016.11.019_b0085","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/1523-1747.ep12277141","article-title":"Effects of antifungal agents on ergosterol biosynthesis in Candida albicans and Trichophyton mentagrophytes: differential inhibitory sites of naphthiomate and miconazole","volume":"85","author":"Nozawa","year":"1985","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.bcp.2016.11.019_b0090","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/S1040-0486(00)90023-1","article-title":"Oral antifungal agents used in dermatology","volume":"11","author":"Pardasani","year":"2000","journal-title":"Curr. Probl. Dermatol."},{"key":"10.1016\/j.bcp.2016.11.019_b0095","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1086\/380796","article-title":"Guidelines for treatment of candidiasis","volume":"38","author":"Pappas","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.bcp.2016.11.019_b0100","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S0924-8579(00)00258-2","article-title":"Current and future antifungal therapy: new targets for antifungal therapy","volume":"16","author":"Vincent","year":"2000","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.bcp.2016.11.019_b0105","first-page":"90","article-title":"The diagnostic and therapeutic approach to fungal infections in critical care settings","volume":"6","author":"Zaragoza","year":"2008","journal-title":"Adv. Sepsis"},{"key":"10.1016\/j.bcp.2016.11.019_b0110","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ijantimicag.2007.03.009","article-title":"Recent advances in antifungal chemotherapy","volume":"30","author":"Petrikkos","year":"2007","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.bcp.2016.11.019_b0115","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ccm.2009.02.001","article-title":"Overview of anti-fungal agents","volume":"30","author":"George","year":"2009","journal-title":"Clin. Chest Med."},{"key":"10.1016\/j.bcp.2016.11.019_b0120","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1086\/523576","article-title":"Posaconazole: a broad-spectrum triazole antifungal agent","volume":"45","author":"Nagappan","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.bcp.2016.11.019_b0125","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1358\/dot.2015.51.12.2421058","article-title":"Triazole antifungals: a review","volume":"51","author":"Peyton","year":"2015","journal-title":"Drugs Today"},{"key":"10.1016\/j.bcp.2016.11.019_b0130","article-title":"New microbial Source of the antifungal allylamine \u201cTerbinafine\u201d","author":"Abdel-Kader","year":"2016","journal-title":"Saudi Pharm. J."},{"key":"10.1016\/j.bcp.2016.11.019_b0135","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2310\/7750.2008.06009","article-title":"Naftifine: a review","volume":"12","author":"Gupta","year":"2008","journal-title":"J. Cutan. Med. Surg."},{"key":"10.1016\/j.bcp.2016.11.019_b0140","doi-asserted-by":"publisher","first-page":"4369","DOI":"10.1128\/AAC.01084-13","article-title":"In vitro antifungal activity of naftifine hydrochloride against dermatophytes","volume":"57","author":"Ghannoum","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bcp.2016.11.019_b0145","doi-asserted-by":"publisher","DOI":"10.1111\/jam.13301","article-title":"Fungal cell membrane-promising drug target for antifungal therapy","author":"Sant","year":"2016","journal-title":"J. Appl. Microbiol."},{"key":"10.1016\/j.bcp.2016.11.019_b0150","first-page":"299","volume":"vol. 1","author":"Mayers","year":"2009"},{"key":"10.1016\/j.bcp.2016.11.019_b0155","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1517\/13543784.9.8.1797","article-title":"New investigational antifungal agents for treating invasive fungal infections","volume":"9","author":"Hossain","year":"2000","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.bcp.2016.11.019_b0160","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1517\/13543784.10.8.1501","article-title":"New developments in chemotherapy for non-invasive fungal infections","volume":"10","author":"Hossain","year":"2001","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.bcp.2016.11.019_b0165","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1128\/AAC.47.4.1179-1186.2003","article-title":"In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis","volume":"47","author":"Andes","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bcp.2016.11.019_b0170","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/nchembio.1496","article-title":"Amphotericin forms an extramembranous and fungicidal sterol sponge","volume":"10","author":"Anderson","year":"2014","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bcp.2016.11.019_b0175","first-page":"759","article-title":"Compounded preparations with nystatin for oral and oromucosal administration","volume":"70","author":"Sklen\u00e1r","year":"2013","journal-title":"Acta Pol. Pharm. Drug Res."},{"issue":"10","key":"10.1016\/j.bcp.2016.11.019_b0180","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.1128\/JCM.00610-08","article-title":"In vitro natamycin susceptibility of ocular isolates of Fusarium and Aspergillus species: comparison of commercially formulated natamycin eye drops to pharmaceutical-grade powder","volume":"46","author":"Lalitha","year":"2008","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.bcp.2016.11.019_b0185","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/1521-4028(200007)40:3<157::AID-JOBM157>3.0.CO;2-1","article-title":"Optimization of the cultivation medium for natamycin production by Streptomyces natalensis","volume":"40","author":"Farid","year":"2000","journal-title":"J. Basic Microbiol."},{"key":"10.1016\/j.bcp.2016.11.019_b0190","doi-asserted-by":"publisher","first-page":"211","DOI":"10.2174\/0929867033368448","article-title":"Polyene macrolide antibiotics and their applications in human therapy","volume":"10","author":"Zotchev","year":"2003","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bcp.2016.11.019_b0195","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.riam.2009.06.003","article-title":"Amphotericin B: side effects and toxicity","volume":"26","author":"Laniado-Labor\u00edn","year":"2009","journal-title":"Rev. Iberoam. Micol."},{"key":"10.1016\/j.bcp.2016.11.019_b0200","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/S1074-5521(01)00046-1","article-title":"Amphotericin biosynthesis in Streptomyces nodosus: deductions from analysis of polyketide synthase and late genes","volume":"8","author":"Caffrey","year":"2001","journal-title":"Chem. Biol."},{"key":"10.1016\/j.bcp.2016.11.019_b0205","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s00253-005-1955-9","article-title":"Amphotericin B","volume":"68","author":"Lemke","year":"2005","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.bcp.2016.11.019_b0210","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/S0966-842X(03)00117-3","article-title":"Antifungal agents: mechanisms of action","volume":"11","author":"Odds","year":"2003","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.bcp.2016.11.019_b0215","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1586\/14787210.3.2.167","article-title":"Liposomal amphotericin B: clinical experience and perspectives","volume":"3","author":"Gibbs","year":"2005","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"10.1016\/j.bcp.2016.11.019_b0220","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1039\/b914961a","article-title":"Natural products as antifungal agents against clinically relevant pathogens","volume":"27","author":"Santo","year":"2010","journal-title":"Nat. Prod. Rep."},{"key":"10.1016\/j.bcp.2016.11.019_b0225","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1128\/AAC.01369-07","article-title":"Efficacy of SPK-843, a novel polyene antifungal, in comparison with amphotericin B, liposomal amphotericin B, and micafungin against murine pulmonary aspergillosis","volume":"52","author":"Kakeya","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bcp.2016.11.019_b0230","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1093\/jac\/49.suppl_1.31","article-title":"Overview of the lipid formulations of amphotericin B","volume":"49","author":"Dupont","year":"2002","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.bcp.2016.11.019_b0235","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1093\/jac\/dkq479","article-title":"Management of invasive fungal infections: a role for polyenes","volume":"66","author":"Chandrasekar","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.bcp.2016.11.019_b0240","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3109\/08982100009031116","article-title":"Cochleates: new lipid-based drug delivery system","volume":"10","author":"Zarif","year":"2000","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.bcp.2016.11.019_b0245","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1128\/AAC.43.8.1975","article-title":"A novel injectable water-soluble amphotericin B-arabinogalactan conjugate","volume":"43","author":"Falk","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bcp.2016.11.019_b0250","doi-asserted-by":"publisher","first-page":"900","DOI":"10.2174\/138955707781662672","article-title":"Recent advances in antifungal agents","volume":"7","author":"Lorand","year":"2007","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.bcp.2016.11.019_b0255","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1345\/aph.1M237","article-title":"Echinocandins: the newest class of antifungals","volume":"43","author":"Sucher","year":"2009","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.bcp.2016.11.019_b0260","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1179\/joc.2011.23.6.319","article-title":"Echinocandins: are they all the same?","volume":"23","author":"Mukherjee","year":"2011","journal-title":"J. Chemother."},{"key":"10.1016\/j.bcp.2016.11.019_b0265","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1086\/505204","article-title":"Anidulafungin: a novel echinocandin","volume":"43","author":"Vazquez","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.bcp.2016.11.019_b0270","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2147\/tcrm.2007.3.1.71","article-title":"Comparison of echinocandin antifungals","volume":"3","author":"Eschenauer","year":"2007","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.bcp.2016.11.019_b0275","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s11908-003-0060-4","article-title":"What\u2019s new in antifungals?","volume":"5","author":"Valgus","year":"2003","journal-title":"Curr. Infect. Dis. Rep."},{"key":"10.1016\/j.bcp.2016.11.019_b0280","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1128\/AAC.47.4.1187-1192.2003","article-title":"In vivo pharmacodynamics of HMR 3270, a Glucan synthase inhibitor, in a murine candidiasis model","volume":"47","author":"Andes","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bcp.2016.11.019_b0285","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw214","article-title":"Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates","author":"Pfaller","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.bcp.2016.11.019_b0290","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1093\/jac\/dkp140","article-title":"Pharmacokinetics and biodistribution of amphotericin B in rats following oral administration in a novel lipid-based formulation","volume":"64","author":"Gershkovich","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.bcp.2016.11.019_b0295","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1080\/13693780500138971","article-title":"An update on antifungal targets and mechanisms of resistance in Candida albicans","volume":"43","author":"Akins","year":"2005","journal-title":"Med. Mycol."},{"key":"10.1016\/j.bcp.2016.11.019_b0300","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1093\/jac\/dkg018","article-title":"Antifungal activity of the echinocandin anidulafungin (VER002, LY-303366) against yeast pathogens: a comparative study with M27-A microdilution method","volume":"51","author":"Arevalo","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.bcp.2016.11.019_b0305","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1046\/j.1469-0691.2003.00489.x","article-title":"Microbial natural products as a source of antifungals","volume":"9","author":"Vicente","year":"2003","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.bcp.2016.11.019_b0310","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.4155\/fmc-2016-0053","article-title":"Sphingolipids as targets for treatment of fungal infections","volume":"8","author":"Rollin-Pinheiro","year":"2016","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.bcp.2016.11.019_b0315","doi-asserted-by":"publisher","first-page":"919","DOI":"10.7164\/antibiotics.44.919","article-title":"Aureobasidins, new antifungal antibiotics taxonomy, fermentation, isolation and properties","volume":"44","author":"Takesako","year":"1991","journal-title":"J. Antibiot."},{"key":"10.1016\/j.bcp.2016.11.019_b0320","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1128\/AAC.44.3.651-653.2000","article-title":"Inhibition of inositol phosphorylceramide synthase by aureobasidin A in Candida and Aspergillus species","volume":"44","author":"Zhong","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bcp.2016.11.019_b0325","first-page":"236","article-title":"AUR1, a novel gene conferring aureobasidin resistance on Saccharomyces cerevisiae: a study of defective morphologies in Aur1p-depleted cells","volume":"251","author":"Hashida-Okado","year":"1996","journal-title":"Mol. Gen. Genet. (Tokyo)"},{"key":"10.1016\/j.bcp.2016.11.019_b0330","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1021\/acsmedchemlett.5b00029","article-title":"Generation of broad-spectrum antifungal drug candidates from the natural product compound aureobasidin A","volume":"6","author":"Wuts","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bcp.2016.11.019_b0335","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1128\/AAC.44.2.368-377.2000","article-title":"Discovery of novel antifungal (1,3)-\u03b2-d-Glucan synthase inhibitors","volume":"44","author":"Onishi","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bcp.2016.11.019_b0340","first-page":"590","article-title":"Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal","volume":"44","author":"Dowell","year":"2004"},{"key":"10.1016\/j.bcp.2016.11.019_b0345","doi-asserted-by":"publisher","first-page":"7343","DOI":"10.1128\/AEM.01257-10","article-title":"Enhancement of the diversity of polyoxins by a thymine-7-hydroxylase homolog outside the polyoxin biosynthesis gene cluster","volume":"76","author":"Zhao","year":"2010","journal-title":"Appl. Environ. Microbiol."},{"key":"10.1016\/j.bcp.2016.11.019_b0350","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1128\/AAC.41.4.863","article-title":"In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species","volume":"41","author":"Zhanel","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bcp.2016.11.019_b0355","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1080\/17512433.2016.1206467","article-title":"Tavaborole \u2013 a treatment for onychomycosis of the toenails","volume":"9","author":"Gupta","year":"2016","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"10.1016\/j.bcp.2016.11.019_b0360","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1126\/science.1142189","article-title":"An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site","volume":"316","author":"Rock","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.bcp.2016.11.019_b0365","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.7164\/antibiotics.42.1749","article-title":"Cispentacin, a new antifungal antibiotic","volume":"42","author":"Konishi","year":"1989","journal-title":"J. Antibiot."},{"key":"10.1016\/j.bcp.2016.11.019_b0370","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.1128\/AAC.48.10.3959-3967.2004","article-title":"Efficacy of PLD-118, a novel inhibitor of Candida isoleucyl-tRNA synthetase, against experimental oropharyngeal and esophageal candidiasis caused by fluconazole-resistant C. albicans","volume":"48","author":"Petraitis","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bcp.2016.11.019_b0375","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3762\/bjoc.4.31","article-title":"Sordarin, an antifungal agent with a unique mode of action","volume":"4","author":"Liang","year":"2008","journal-title":"Beilstein J. Org. Chem."},{"key":"10.1016\/j.bcp.2016.11.019_b0380","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1128\/AAC.42.11.2863","article-title":"Sordarins: in vitro activities of new antifungal derivatives against pathogenic yeasts, Pneumocystis carinii and filamentous fungi","volume":"42","author":"Herreros","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bcp.2016.11.019_b0385","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.mycres.2009.02.011","article-title":"Distribution of the antifungal agents sordarins across filamentous fungi","volume":"113","author":"Vicente","year":"2009","journal-title":"Mycol. Res."},{"key":"10.1016\/j.bcp.2016.11.019_b0390","unstructured":"M. Serrano-Wu, X. Du, N. Balasubramanian, D.R. St. Laurent, Thio derivatives of sordarin as antifungal agents, US 6,436,930 B1 (2002)."},{"key":"10.1016\/j.bcp.2016.11.019_b0395","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/S0960-894X(02)00290-1","article-title":"Synthesis and evaluation of N-substituted 1,4-oxazepanyl sordaricins as selective fungal EF-2 inhibitors","volume":"12","author":"Kaneko","year":"2002","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bcp.2016.11.019_b0400","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/j.bmcl.2009.01.051","article-title":"FR290581, a novel sordarin derivative: synthesis and antifungal activity","volume":"19","author":"Hanadate","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bcp.2016.11.019_b0405","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1146\/annurev.bi.54.070185.001555","article-title":"Molecular biology and genetics of tubulin","volume":"54","author":"Cleveland","year":"1985","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.bcp.2016.11.019_b0410","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1042\/bj0330240","article-title":"Studies in the biochemistry of micro-organisms, Griseofulvin, C17H17O6Cl, a metabolic product of Penicillium griseo-fulvum Dierckx","volume":"33","author":"Oxford","year":"1939","journal-title":"Biochem. J."},{"key":"10.1016\/j.bcp.2016.11.019_b0415","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1017\/S0269915X03002064","article-title":"Antifungal agents: their diversity and increasing sophistication","volume":"17","author":"Odds","year":"2003","journal-title":"Mycologist"},{"key":"10.1016\/j.bcp.2016.11.019_b0420","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.drudis.2008.11.013","article-title":"Targeting virulence: a new paradigm for antifungals","volume":"14","author":"Gauwerky","year":"2009","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bcp.2016.11.019_b0425","series-title":"Medical Mycology: The Pathogenic Fungi and the Pathogenic Actinomycetes","author":"Rippon","year":"1982"},{"key":"10.1016\/j.bcp.2016.11.019_b0430","doi-asserted-by":"publisher","first-page":"7148","DOI":"10.1073\/pnas.1601774113","article-title":"Structures of trehalose-6-phosphate phosphatase from pathogenic fungi reveal the mechanisms of substrate recognition and catalysis","volume":"113","author":"Miao","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.bcp.2016.11.019_b0435","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1002\/pro.2411","article-title":"Crystal structures of the fungal pathogen Aspergillus fumigatus protein farnesyltransferase complexed with substrates and inhibitors reveal features for antifungal drug design","volume":"23","author":"Mabanglo","year":"2014","journal-title":"Protein Sci."},{"key":"10.1016\/j.bcp.2016.11.019_b0440","doi-asserted-by":"publisher","first-page":"2818","DOI":"10.1073\/pnas.0813394106","article-title":"Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease","volume":"106","author":"Cowen","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.bcp.2016.11.019_b0445","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1021\/id5000212","article-title":"Chemical genomics-based antifungal drug discovery: targeting glycosylphosphatidylinositol (GPI) precursor biosynthesis","volume":"1","author":"Mann","year":"2015","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.bcp.2016.11.019_b0450","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/msb.2011.31","article-title":"Cross-species discovery of syncretic drug combinations that potentiate the antifungal fluconazole","volume":"7","author":"Spitzer","year":"2011","journal-title":"Mol. Syst. Biol."},{"key":"10.1016\/j.bcp.2016.11.019_b0455","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1016\/j.celrep.2015.10.018","article-title":"An antifungal combination matrix identifies a rich pool of adjuvant molecules that enhance drug activity against diverse fungal pathogens","volume":"13","author":"Robbins","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.bcp.2016.11.019_b0460","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1016\/j.cell.2014.10.044","article-title":"Unraveling the biology of a fungal meningitis pathogen using chemical genetics","volume":"159","author":"Brown","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2016.11.019_b0465","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3389\/fmolb.2016.00022","article-title":"Systematic identification of anti-fungal drug targets by a metabolic network approach","volume":"3","author":"Kaltdorf","year":"2016","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.bcp.2016.11.019_b0470","doi-asserted-by":"publisher","first-page":"e1001124","DOI":"10.1371\/journal.ppat.1001124","article-title":"HapX-mediated adaption to iron starvation is crucial for virulence of Aspergillus fumigatus","volume":"6","author":"Schrettl","year":"2010","journal-title":"PLoS Pathol."},{"key":"10.1016\/j.bcp.2016.11.019_b0475","doi-asserted-by":"publisher","first-page":"4727","DOI":"10.1128\/AAC.00946-15","article-title":"Hsp70 and the cochaperone StiA (Hop) orchestrate Hsp90-mediated caspofungin tolerance in Aspergillus fumigatus","volume":"59","author":"Lamoth","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bcp.2016.11.019_b0480","article-title":"The anti-Aspergillus drug pipeline: is the glass half full or empty?","author":"Osherov","year":"2016","journal-title":"Med. Mycol."},{"key":"10.1016\/j.bcp.2016.11.019_b0485","doi-asserted-by":"publisher","first-page":"13039","DOI":"10.1073\/pnas.1511197112","article-title":"Disulphide-reduced psoriasin is a human apoptosis inducing broad-spectrum fungicide","volume":"112","author":"Heina","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.bcp.2016.11.019_b0490","doi-asserted-by":"publisher","first-page":"5145","DOI":"10.1128\/AAC.00683-15","article-title":"Hitting the caspofungin salvage pathway of human-pathogenic fungi with the novel lasso peptide humidimycin (MDN-0010)","volume":"59","author":"Valiante","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bcp.2016.11.019_b0495","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nri1255","article-title":"Immunity to fungal infections","volume":"4","author":"Romani","year":"2004","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bcp.2016.11.019_b0500","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1177\/1087057113496847","article-title":"A high throughput screening assay for fungicidal compounds against: Cryptococcus neoformans","volume":"19","author":"Rabjohns","year":"2014","journal-title":"J. Biomol. Screen."},{"key":"10.1016\/j.bcp.2016.11.019_b0505","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1177\/1087057111433459","article-title":"A new approach to drug discovery: high-throughput screening of microbial natural extracts against Aspergillus fumigatus Using Resazurin","volume":"17","author":"Monteiro","year":"2012","journal-title":"J. Biomol. Screen."},{"key":"10.1016\/j.bcp.2016.11.019_b0510","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1086\/524071","article-title":"Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact","volume":"46","author":"Kanafani","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.bcp.2016.11.019_b0515","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1586\/eri.09.18","article-title":"Antifungal drug resistance mechanisms","volume":"7","author":"Peman","year":"2009","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"10.1016\/j.bcp.2016.11.019_b0520","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3389\/fmed.2016.00011","article-title":"Emerging threats in antifungal-resistant fungal pathogens","volume":"3","author":"Sanglard","year":"2016","journal-title":"Front. Med."},{"key":"10.1016\/j.bcp.2016.11.019_b0525","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1556\/AMicr.54.2007.3.1","article-title":"Pathogenicity and drug resistance in Candida albicans and other yeast species. A review","volume":"54","author":"Mishra","year":"2007","journal-title":"Acta Microbiol. Immunol. Hung."},{"key":"10.1016\/j.bcp.2016.11.019_b0530","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.archoralbio.2011.03.007","article-title":"New antimicrobial therapies used against fungi present in subgingival sites \u2013 a brief review","volume":"56","author":"Sardi","year":"2011","journal-title":"Arch. Oral Biol."},{"key":"10.1016\/j.bcp.2016.11.019_b0535","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1128\/AAC.01467-10","article-title":"Differential requirement of the transcription factor Mcm1 for activation of the Candida albicans multidrug efflux pump MDR1 by its regulators Mrr1 and Cap1","volume":"55","author":"Mogavero","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bcp.2016.11.019_b0540","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1099\/00221287-146-11-2743","article-title":"A novel multidrug efflux transporter gene of the major facilitator superfamily from Candida albicans (FLU1) conferring resistance to fluconazole","volume":"146","author":"Calabrese","year":"2000","journal-title":"Microbiology"},{"key":"10.1016\/j.bcp.2016.11.019_b0545","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1128\/EC.00103-08","article-title":"A gain-of-function mutation in the transcription factor Upc2p causes upregulation of ergosterol biosynthesis genes and increased fluconazole resistance in a clinical Candida albicans isolate","volume":"7","author":"Dunkel","year":"2008","journal-title":"Eukaryot. Cell"},{"key":"10.1016\/j.bcp.2016.11.019_b0550","doi-asserted-by":"publisher","first-page":"335","DOI":"10.2217\/fmb.11.4","article-title":"Azole resistance in Aspergillus fumigatus: a new challenge in the management of invasive aspergillosis?","volume":"6","author":"Snelders","year":"2011","journal-title":"Future Microbiol."},{"key":"10.1016\/j.bcp.2016.11.019_b0555","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1128\/AAC.44.10.2693-2700.2000","article-title":"Upregulation of ERG genes in Candida species by azoles and other sterol biosynthesis inhibitors","volume":"44","author":"Henry","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bcp.2016.11.019_b0560","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1128\/AAC.41.7.1482","article-title":"Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus","volume":"41","author":"White","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bcp.2016.11.019_b0565","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1128\/AAC.42.11.2932","article-title":"Distinct patterns of gene expression associated with development of fluconazole resistance in serial Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis","volume":"42","author":"Lopez-Ribot","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bcp.2016.11.019_b0570","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1099\/jmm.0.045054-0","article-title":"Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options","volume":"62","author":"Sardi","year":"2013","journal-title":"J. Med. Microbiol."},{"key":"10.1016\/j.bcp.2016.11.019_b0575","doi-asserted-by":"publisher","first-page":"e1002585","DOI":"10.1371\/journal.ppat.1002585","article-title":"Fungal biofilms","volume":"8","author":"Fanning","year":"2012","journal-title":"PLoS Pathol."},{"key":"10.1016\/j.bcp.2016.11.019_b0580","doi-asserted-by":"publisher","first-page":"a019729","DOI":"10.1101\/cshperspect.a019729","article-title":"Fungal biofilms, drug resistance, and recurrent infection","volume":"4","author":"Desai","year":"2014","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.bcp.2016.11.019_b0585","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.mib.2006.06.007","article-title":"Candida albicans biofilm development, modeling a host\u2013pathogen interaction","volume":"9","author":"Nett","year":"2006","journal-title":"Curr. Opin. Microbiol."},{"key":"10.1016\/j.bcp.2016.11.019_b0590","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1128\/EC.05126-11","article-title":"Interface of Candida albicans biofilm matrix-associated drug resistance and cell wall integrity regulation","volume":"10","author":"Nett","year":"2011","journal-title":"Eukaryot. Cell"},{"key":"10.1016\/j.bcp.2016.11.019_b0595","doi-asserted-by":"publisher","first-page":"4092","DOI":"10.1073\/pnas.1421437112","article-title":"Community participation in biofilm matrix assembly and function","volume":"112","author":"Mitchell","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.bcp.2016.11.019_b0600","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.mib.2013.03.007","article-title":"Candida albicans biofilms: building a heterogeneous, drug-tolerant environment","volume":"16","author":"Bonhomme","year":"2013","journal-title":"Curr. Opin. Microbiol."},{"key":"10.1016\/j.bcp.2016.11.019_b0605","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1128\/AAC.46.6.1773-1780.2002","article-title":"Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins","volume":"46","author":"Kuhn","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bcp.2016.11.019_b0610","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.riam.2011.06.003","article-title":"Epidemiology of invasive fungal infection in solid organ transplant","volume":"28","author":"Montejo","year":"2011","journal-title":"Rev. Iberoam. Micol."},{"key":"10.1016\/j.bcp.2016.11.019_b0615","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1128\/AAC.02157-15","article-title":"Activity of isavuconazole and other azoles against Candida clinical isolates and yeast model systems with known azole resistance mechanisms","volume":"60","author":"Sanglard","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bcp.2016.11.019_b0620","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1128\/AAC.47.3.1120-1124.2003","article-title":"A point mutation in the 14\u03b1-sterol demethylase gene cyp51A contributes to itraconazole resistance in Aspergillus fumigatus","volume":"47","author":"Diaz-Guerra","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bcp.2016.11.019_b0625","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.drup.2007.04.002","article-title":"Resistance to echinocandin-class antifungal drugs","volume":"10","author":"Perlin","year":"2007","journal-title":"Drug Resist. Update"},{"key":"10.1016\/j.bcp.2016.11.019_b0630","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1128\/AAC.01162-08","article-title":"Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints","volume":"53","author":"Garcia-Effron","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bcp.2016.11.019_b0635","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s11046-010-9342-1","article-title":"Molecular mechanisms of resistance to 5-fluorocytosine in laboratory mutants of Candida glabrata","volume":"171","author":"Vandeputte","year":"2011","journal-title":"Mycopathologia"},{"key":"10.1016\/j.bcp.2016.11.019_b0640","doi-asserted-by":"publisher","first-page":"e1001692","DOI":"10.1371\/journal.pbio.1001692","article-title":"Fitness trade-offs restrict the evolution of resistance to amphotericin B","volume":"11","author":"Vincent","year":"2013","journal-title":"PLoS Biol."},{"key":"10.1016\/j.bcp.2016.11.019_b0645","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2016.11.019_b0650","doi-asserted-by":"publisher","first-page":"7121","DOI":"10.1128\/AAC.03707-14","article-title":"The clinical candidate VT-1161 is a highly potent inhibitor of Candida albicans CYP51 but fails to bind the human enzyme","volume":"58","author":"Warrilow","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bcp.2016.11.019_b0655","doi-asserted-by":"publisher","first-page":"5567","DOI":"10.1128\/AAC.00185-15","article-title":"Efficacy of the clinical agent VT-1161 against fluconazole-sensitive and -resistant Candida albicans in a murine model of vaginal Candidiasis","volume":"59","author":"Garvey","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bcp.2016.11.019_b0660","first-page":"42","article-title":"The novel fungal Cyp51 inhibitor VT-1129 demonstrates potent in vivo activity against cryptococcal meningitis with an improved formulation","volume":"57","author":"Najvar","year":"2014","journal-title":"Mycoses"},{"key":"10.1016\/j.bcp.2016.11.019_b0665","doi-asserted-by":"publisher","first-page":"4308","DOI":"10.1128\/AAC.00234-15","article-title":"Antifungal activities of SCY-078 (MK-3118) and standard antifungal agents against clinical non-Aspergillus mold isolates","volume":"59","author":"Lamoth","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bcp.2016.11.019_b0670","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1128\/AAC.04857-14","article-title":"Efficacy of the investigational echinocandin ASP9726 in a guinea pig model of invasive pulmonary aspergillosis","volume":"59","author":"Wiederhold","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bcp.2016.11.019_b0675","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.bmcl.2013.12.116","article-title":"Synthesis and antifungal activity of ASP9726, a novel echinocandin with potent Aspergillus hyphal growth inhibition","volume":"24","author":"Morikawa","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bcp.2016.11.019_b0680","doi-asserted-by":"publisher","first-page":"5892","DOI":"10.1128\/AAC.05954-11","article-title":"T-2307 causes collapse of mitochondrial membrane potential in yeast","volume":"56","author":"Shibata","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bcp.2016.11.019_b0685","doi-asserted-by":"publisher","first-page":"12809","DOI":"10.1073\/pnas.1608304113","article-title":"F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase","volume":"113","author":"Oliver","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.bcp.2016.11.019_b0690","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1021\/acsinfecdis.5b00134","article-title":"Antitumor\/antifungal celecoxib derivative AR-12 is a non-nucleoside inhibitor of the ANL-family adenylating enzyme acetyl CoA synthetase","volume":"2","author":"Koselny","year":"2016","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.bcp.2016.11.019_b0695","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1128\/AAC.02336-15","article-title":"In vitro activity of ASP2397 against Aspergillus isolates with or without acquired azole resistance mechanisms","volume":"60","author":"Arendrup","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bcp.2016.11.019_b0700","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S0723-2020(00)80062-4","article-title":"The discovery of enfumafungin, a novel antifungal compound produced by an endophytic Hormonema species biological activity and taxonomy of the producing organisms","volume":"23","author":"Pel\u00e1ez","year":"2000","journal-title":"Syst. Appl. Microbiol."},{"key":"10.1016\/j.bcp.2016.11.019_b0705","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1128\/AAC.02145-13","article-title":"Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant Candida species and Aspergillus species isolates","volume":"58","author":"Jim\u00e9nez-Ortigosa","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bcp.2016.11.019_b0710","doi-asserted-by":"publisher","first-page":"5813","DOI":"10.1016\/j.bmcl.2015.10.011","article-title":"Novel orally active inhibitors of b-1,3-glucan synthesis derived from enfumafungin","volume":"25","author":"Apgar","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bcp.2016.11.019_b0715","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1128\/AAC.03944-14","article-title":"The investigational agent E1210 is effective in treatment of experimental invasive candidiasis caused by resistant Candida albicans","volume":"59","author":"Wiederhold","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"issue":"9","key":"10.1016\/j.bcp.2016.11.019_b0720","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1093\/jac\/dkv140","article-title":"Stepwise emergence of azole, echinocandin and amphotericin B multidrug resistance in vivo in Candida albicans orchestrated by multiple genetic alterations","volume":"70","author":"Jensen","year":"2015","journal-title":"J. Antimicrob. Chemother."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295216304221?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295216304221?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T20:31:33Z","timestamp":1692563493000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295216304221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":144,"alternative-id":["S0006295216304221"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2016.11.019","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antifungals","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2016.11.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}